New Data Show Osimertinib Effective as First-Line Treatment of NSCLC with EGFR Mutation

In the News: May 2016 - Lung Cancer, Web Exclusive
Lilly Ostrovsky

Last November, osimertinib (Tagrisso), a third-generation EGFR tyrosine kinase inhibitor (TKI) that targets EGFR mutations, including T790M, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with metastatic EGFR T790M mutation–positive non–small-cell lung cancer (NSCLC) whose disease progressed during or after EGFR TKI therapy.

In April 2016, data from a new study were presented at the 2016 European Lung Cancer Conference in Geneva, Switzerland, indicating that osimertinib is associated with a high objective response rate (ORR) and prolonged progression-free survival (PFS) in patients with NSCLC and EGFR mutation who are receiving osimertinib as first-line treatment.

“The overall response rate was among the best reported for first-line therapy of EGFR-mutated NSCLC. The progression-free survival results are exciting, well exceeding the historical control rates of 10 to 13 months with first- or second-generation drugs. Many of the patients have not had disease progression on the study and are still benefitting from treatment,” said Suresh Ramalingam, MD, Professor, Emory School of Medicine, Atlanta, GA.

The study included 60 patients with locally advanced or metastatic EGFR mutation–positive NSCLC who had participated in 2 phase 1 expansion cohorts of the AURA clinical trial. Overall, patients were randomized in a 1:1 ratio to receive osimertinib 80 mg or 160 mg daily, and the median follow-up was 16.6 months.

The overall ORR was 77%; –the ORR was 67% in patients taking 80 mg osimertinib and 87% in patients taking 160 mg osimertinib. The median progression-free survival was 19.3 months with 160 mg osimertinib, and was not yet reached with 80 mg osimertinib. The most common adverse events with both doses of osimertinib included diarrhea, stomatitis, and paronychia.

The results demonstrated that patients who had disease progression did not have T790M mutation as the mechanism of resistance, suggesting that “we may be changing the biology of the disease with the use of first-line osimertinib,” said Dr Ramalingam.

A phase 3 clinical trial comparing osimertinib with erlotinib or gefitinib for the first-line treatment of NSCLC is being planned to confirm these findings.

Related Items
NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer
Wayne Kuznar
August 2018 Vol 11, Special Issue published on August 20, 2018 in Lung Cancer
Pembrolizumab as a First-Line Standard-of-Care Option in Advanced Non–Small-Cell Lung Cancer See also Value-Based Care
Wayne Kuznar
August 2018 Vol 11, Special Issue published on August 20, 2018 in Lung Cancer
A “Gold Standard” for Population Health? Revisiting the FDA’s Relationship with the Hippocratic Oath
Gillian Woollett, MA, DPhil , Bruce S. Pyenson, FSA, MAAA
Web Exclusives published on May 25, 2018 in Hot Topics, Web Exclusive
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 10, 2018 in FDA Approvals, News & Updates, Lung Cancer
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights published on August 24, 2017 in Lung Cancer
Last modified: May 24, 2016
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME